Supplementary Information
The objective of this study was to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable The online version contains supplementary material available at 10.1007/s10637-023-01341-y.